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Purpose: To evaluate the Recurrence Score® of the quantitative 12-multigene expression assay 
and to determine risk groups based on the continuous Recurrence Score® in Korean patients.
Method: A total of 95 patients with pathological T3N0 tumors and mismatch repair-proficient 
tumors were enrolled. The Recurrence Score® was used to classify risk groups (low risk, ,30; 
intermediate risk, 30–40; high risk, $41).
Results: Fifty-four patients (56.8%) were aged over 70 years. There were 49 men (51.6%) 
and 56 cases of right-sided colon cancer (58.9%). Eight cases (8.4%) had well-differentiated 
tumors, and 86 cases (90.5%) showed moderate differentiation. Only one case (1.1%) had a 
poorly differentiated tumor. Three patients (3.2%) had lymphovascular invasion. Sixty-one 
patients were identified as low risk (64.2%) and 34 patients as intermediate risk (35.8%). There 
were no high-risk patients. Although not significant, the 3-year recurrence risk increased with 
the Recurrence Score®.
Conclusion: Distribution patterns of risk groups based on the Recurrence Score®, particularly 
the absence of a high-risk group, were different from the prior validation studies. These findings 
suggest that ethnic differences between Koreans and Western patients are potential contributing 
factors for different gene expressions in the quantitative 12-multigene expression assay.
Keywords: colonic neoplasms, gene expression, adjuvant chemotherapy, ethnic groups
Introduction
Colorectal cancer (CRC) is the third most common malignancy in the world.1 In Asia, 
including Korea, CRC is currently the fourth leading cause of mortality by cancer, and 
its prevalence is increasing.2 After curative-intent resection of colon cancer, adjuvant 
therapy is performed to eliminate any potential source of disease recurrence. The 
benefits of adjuvant chemotherapy have been widely proven for stage III colon cancer; 
thus, it has become a standard treatment for such cases. However, the role of adjuvant 
chemotherapy remains less clear in patients with stage II colon cancer.3–5
Outcomes of stage II colon cancer vary;6,7 accordingly, risk stratification within 
stage II disease has been performed using clinical and pathologic variables. The cur-
rent National Comprehensive Cancer Network guidelines recommend adjuvant che-
motherapy for stage II colon cancer when patients have a pathological (p)T4 lesion, 
intestinal perforation or obstruction, lymphovascular invasion, perineural invasion, 
poorly differentiated histology, or fewer than 12 lymph nodes examined.8 However, 
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there are no convincing data to predict the recurrence risk 
accurately for stage II disease. Thus, it is necessary to identify 
more effective predictors that can be used in addition to the 
traditional clinicopathologic parameters to assist in recur-
rence risk stratification and treatment decision-making for 
patients with stage II colon cancer.
Multiple-gene analysis can provide more reliable insight 
into tumor biology than single-gene analysis, and it can also 
yield more robust information regarding each prognosis, 
diagnosis, and response to treatment. In recent years, several 
groups have developed multigene panel assays to determine 
the prognosis of patients with stage II colon cancer.9–11 One 
of these assays is the Oncotype DX® Colon Cancer Assay 
(Genomic Health, Redwood City, CA, USA), which utilizes 
a quantitative reverse transcription-polymerase chain reaction 
(RT-PCR)-based panel test using 12 genes. This panel was 
validated as a significant predictor for recurrence in stage II 
colon cancer.12–14
Most validation studies have been performed in Western 
countries;12–14 however, Ollberding et al15 suggested that 
ethnic difference may contribute to CRC risk through genetic 
susceptibility in their multiethnic cohort study. Thus, we 
postulated that gene expression patterns of the quantitative 
12-multigene expression assay could differ between Western 
and Korean patients. The purpose of this pilot study was 
to investigate 1) the Recurrence Score® of the quantitative 
12-multigene expression assay in Korean patients with stage 
II colon cancer and 2) the association between recurrence risk 
and the Recurrence Score® of the quantitative 12-multigene 
expression assay.
Methods
Patients and materials
This study included a retrospective study (n=56) and a pro-
spective study (n=39). Eligibility criteria for the retrospective 
study was as follows: Korean patients with biopsy-proven 
adenocarcinoma derived from the colon who underwent 
curative resection for colon cancer from January 2008 
to December 2010; a postoperative pathologic report of 
American Joint Committee on Cancer stage II colon cancer 
with mismatch repair (MMR) gene-proficiency (low or stable 
microsatellite instability); no adjuvant chemotherapy; and 
available freshly frozen tumor tissues. Exclusion criteria were 
high-risk features, including the presence of a pT4 lesion, 
MMR gene-deficiency (high microsatellite instability),16 and 
a lack of freshly frozen tumor tissue. We obtained freshly 
frozen tumor tissue samples and complete medical records 
of 56 patients who satisfied the eligibility criteria. Age, 
sex, tumor location, and evidence of bowel obstruction or 
perforation were obtained from clinical records. Events of 
recurrence were included as local and systemic recurrences. 
Local recurrence was defined as tumor regrowth in the vicin-
ity of the primary tumor site, and systemic recurrence was 
defined as tumor recurrence in the distant organs. We used 
all fresh frozen samples, and this methodology differed from 
that used in the original study, which used fixed paraffin-
embedded tissue samples. Unfortunately, we did not compare 
RNA quality between paraffin-embedded tissue and fresh 
frozen tissue samples. However, it has been reported that 
fresh frozen tissue preserves histologic cellular architecture 
and generates good-quality RNA.17
The prospective study enrolled 39 patients from January to 
December 2012 using the same eligibility criteria as were used 
for retrospective enrollment. Patients who provided written 
informed consent were enrolled, and this study was approved 
by the institutional review board of Yonsei University Health 
System (number 4-2011-0888). The tumor tissues were stored 
in the Severance Hospital Gene Bank, which has been in 
operation since 2005. Tumor samples were obtained within 
1 hour after surgical resection, transferred to the Gene Bank 
immediately, and frozen with liquid nitrogen. Specimens were 
stored at -80°C until further processing.
recurrence score®
The 12-multigene Recurrence Score® was calculated using 
the prespecified genes and algorithm that were previ-
ously validated12 and recognized cutoff points for low-, 
intermediate-, and high-recurrence risk groups (Recurrence 
Scores of ,30, 30–40, and $41, respectively).
endpoints
The primary endpoint was to evaluate the Recurrence Score® of 
the quantitative 12-multigene expression assay and to determine 
risk groups based on a continuous Recurrence Score® in Korean 
patients with stage II colon cancer. The secondary end point 
was to evaluate the relationship between the continuous 
Recurrence Score® and the 3-year recurrence risk.
histopathologic data
Tumor grade and type were centrally assessed according 
to the College of American Pathologists Consensus State-
ment by an academic surgical pathologist with subspecialty 
expertise in gastrointestinal pathology.18 Data for pathologic 
T stage, number of nodes examined, lymphovascular inva-
sion, perineural invasion, and histologic grade were recorded. 
MMR gene status was assessed in accordance with the 
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consensus definitions of the National Cancer Institute, as 
previously described.19
gene expression analysis
rna extraction
Total RNA extraction was performed using TRIzol® reagent 
according to the manufacturer’s instructions (Life Technologies, 
Carlsbad, CA, USA). After RNA isolation, total RNA was 
checked for the quantity, purity, and integrity of the 18S and 
28S ribosomal bands. Total RNA concentration was determined 
using a Nanodrop spectrophotometer ND-1000 (Thermo Fisher 
Scientific, Waltham, MA, USA). For each sample quantity 
tested, RNA degradation was assessed using the Agilent 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, 
USA) (Figure 1).
reverse transcription
The RT reaction was carried out with 1 μg of total RNA 
using the QuantiTect® Reverse Transcriptase Kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s 
instructions.
Quantitative Pcr (qPcr) and gene-expression analysis
cDNA for target genes (BGN, MYC, FAP, GADD45B, INHBA, 
MK167, MYBL2, UBB) and reference genes (ATP5E, GPX1, 
PGK1, UBB, and VDAC2) was distributed into 96-well plates 
and PCR forward and reverse primer and TaqMan probes 
were added. The TaqMan® probes and primers were designed 
as previously described.20 The primer and probe sequences 
used are presented in Table 1. Oligonucleotides were pur-
chased from Cosmogenetech Co., Ltd. (Seoul, Korea). In this 
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Figure 1 Total rna quality control.
Notes: (A) The total rna sample is shown as 18s and 28s bands by electrophoresis on a 1% formaldehyde gel. (B and C) each sample was assessed for integrity using 
the agilent Bioanalyzer 2100. The bioanalyzer software generates a gel-like image and an electropherogram. The rna quality was determined by visual inspection of the 
electropherogram, 260/280 and 260/230 ratio, concentrations, and the rin.
Abbreviations: cont, control; DX, sample number; rin, rna integrity number.
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study, TaqMan probes had a fluorescein (6-FAM®) 5′-reporter 
and a Black Hole Quencher®-1 (BHQ-1®) 3′-quencher. qPCR 
was performed using a fluorescence-based real-time detec-
tion system (ABI PRISM 7000 sequence detection system; 
Applied Biosystems, Foster City, CA, USA) according to 
the manufacturer’s instructions. Reactions were performed 
in a 25 μL volume with cDNA equivalent to 1 μg total RNA. 
The final primer and probe concentrations were 0.9 μmol/L 
(primers) and 0.25 μmol/L (probes). PCR cycling conditions 
were 95°C for one cycle of 10 minutes, followed by 43 cycles 
of 20 seconds at 95°C then 45 seconds at 60°C. Each gene 
assay was run in triplicate wells.
reference gene normalization
Normalization was performed using the average expression 
of the five reference genes (ATP5E, GPX1, PGK1, UBB, and 
VDAC2). The mean cycle threshold (Ct) value for each gene was 
subtracted from the mean Ct for the five reference genes.20
statistical analysis
All data are described as frequency and percentage. Differ-
ences among groups were analyzed with the chi-square test 
or Fisher’s exact test. Univariate and multivariate Cox regres-
sion analyses were used to estimate the hazard ratio (HR) 
and 95% confidence interval (CI). A rug plot was displayed 
to confirm the relationship between observed and predicted 
risk. All tests were two-sided, and a P-value of 0.05 was 
considered to be statistically significant. Statistical analyses 
were conducted using R project for Statistical Computing, 
Version 2.12.0 (R Development Core Team, Vienna, Austria) 
and SPSS software version 20.0 for Windows (SPSS Corp., 
Chicago, IL, USA).
Results
Demographics
Fifty-four patients (56.8%) were aged over 70 years and the 
mean age was 69.6 years (range, 43–85). The patient group 
consisted of 49 (51.6%) men and 46 (48.4%) women. Fifty-
six carcinomas (58.9%) were located in the right-sided colon, 
and 39 (41.1%) were in the left-sided colon. Eight cases 
(8.4%) had well-differentiated tumors, and 86 cases (90.5%) 
showed moderate differentiation. Only one case (1.1%) had 
a poorly differentiated tumor. Three patients (3.2%) had 
lymphovascular invasion (+) tumors and two patients (2.1%) 
had perineural invasion (+) tumors.
There were no differences in demographics between the 
retrospective and prospective cohorts except for the number 
of lymph nodes examined. In the retrospective cohort, nine 
patients (9.5%) had fewer than 12 harvested lymph nodes 
in the specimen; however, all patients had 12 or more nodes 
in the prospective cohort. Detailed demographics are sum-
marized in Table 2.
Distribution of risk groups based on 
recurrence score®
The 12-multigene Recurrence Score® ranged from 0 to 39, 
with a median score of 28 (interquartile range, 20.3–31.8) 
and a mean of 23.3 (±11.4 standard deviation). Risk groups 
were classified based on the calculated Recurrence Score® 
(low risk, ,30; intermediate risk, 30–40; high risk, $41). 
Sixty-one patients were identified as low risk (64.2%) and 
Table 1 sequences of TaqMan probes and Pcr primers
Gene Oligo Sequence
ATP5E Forward ccgcTTTcgcTacagcaT
reverse TgggagTaTcggaTgTagcTg
Probe TccagccTgTcTccagTaggccac
BGN Forward gagcTccgcaaggaTgac
reverse cTTgTTgTTcaccaggacga
Probe caagggTcTccagcaccTcTacgc
MYC Forward TcccTccacTcggaaggacTa
reverse cggTTgTTgcTgaTcTgTcTca
Probe TcTgacacTgTccaacTTgacccTcTT
FAP Forward cTgaccagaaccacggcT
reverse ggaagTgggTcaTgTggg
Probe cggccTgTccacgaaccacTTaTa
GADD45B Forward acccTcgacaagaccacacT
reverse TgggagTTcaTgggTacaga
Probe aacTTcagccccagcTcccaagTc
GPX1 Forward gcTTaTgaccgaccccaa
reverse aaagTTccaggcaacaTcgT
Probe cTcaTcaccTggTcTccggTgTgT
INHBA Forward gTgcccgagccaTaTagca
reverse cggTagTggTTgaTgacTgTTga
Probe acgTccgggTccTcacTgTccTTcc
MK167 Forward cggacTTTgggTgcgacTT
reverse TTacaacTcTTccacTgggacgaT
Probe ccacTTgTcgaaccaccgcTcgT
MYBL2 Forward gccgagaTcgccaagaTg
reverse cTTTTgaTggTagagTTccagTgaTTc
Probe cagcaTTgTcTgTccTcccTggca
PGK1 Forward agagccagTTgcTgTagaacTcaa
reverse cTgggccTacacagTccTTca
Probe TcTcTgcTgggcaaggaTgTTcTgTTc
UBB Forward gagTcgacccTgcaccTg
reverse gcgaaTgccaTgacTgaa
Probe aaTTaacagccaccccTcaggcg
VDAC2 Forward acccacggacagacTTgc
reverse agcTTTgccaaggTcagc
Probe cgcgTccaaTgTgTaTTccTccaT
Notes: The TaqMan probe consists of an oligonucleotide with a 5′-reporter dye 
(6-FaM®) and a 3′-quencher dye (BhQ®-1). Primers and probes shown were used 
for analysis of ATP5E. BGN, MYC, FAP, GADD45B, GPX1, INHBA, MK167, MYBL2, 
PGK1, UBB, and VDAC2.
Abbreviations: Pcr, Polymerase chain reaction; BhQ®-1, Black hole Quencher®-1; 
FaM, .
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34 as intermediate risk (35.8%). There were no high-risk 
patients (Table 3).
relationship between recurrence score® 
and recurrence risk
To evaluate the relationship between the continuous 
Recurrence Score® and the 3-year recurrence risk, we 
performed subgroup analyses in the retrospective cohort. 
The median follow-up time was 31 months. During the 
follow-up period, four patients (4.2%) developed recurrence. 
Three cases were in the low-risk group and one was in the 
intermediate-risk group (Table 4). In the primary analysis 
based on the Cox model, although not significant, the 3-year 
recurrence risk increased with the Recurrence Score® (HR 
per interquartile range, 0.52; 95% CI, 0.19–1.39; P=0.58; 
Figure 2).
Conventional clinical and pathologic factors includ-
ing age, sex, tumor location, tumor grade, and number of 
lymph nodes did not show any significant associations with 
recurrence-free survival in the univariate and multivariate 
analyses using the Cox proportional hazard model. Simi-
larly, risk assessment based on the National Comprehensive 
Cancer Network guidelines was not a significant risk factor 
for recurrence-free survival, with a HR of 1.41 (95% CI, 
0.15–13.58; P=0.767; Table 5).
Discussion
We hypothesized that gene expression patterns of Korean 
patients may be different from those of Western patients. 
Thus, we determined gene expression using the quantitative 
12-multigene expression assay, Recurrence Scores®, and 
risk groups (low, intermediate, or high risk). The distribu-
tion of risk groups based on Recurrence Score® showed 
that majority of patients (n=61, 64.2%) were in the low-
risk group and the remaining were in the intermediate-risk 
group (35.8%). There were no high-risk patients. The dis-
tribution pattern of risk groups, particularly the absence of 
a high-risk group, was quite different from the published 
validation studies.12–14 These results suggest that ethnic dif-
ferences between Korean and Western patients may play 
a role in the observed differences in gene expression from 
the quantitative 12-multigene expression assay. However, 
we acknowledge that other underlying factors that were 
not considered in this study might have influenced dif-
ferences in gene expression. In addition, the Recurrence 
Score® predicted a recurrence risk in the previous validation 
studies,12–14 and we also found that, although not significant, 
Recurrence Score® was associated with an increased 3-year 
recurrence risk. The nonsignificant result could be attributed 
to the small study sample.
Detailed clinical and pathologic variables of major vali-
dation studies are summarized in Table 3. Upon a review of 
the literature, the distribution pattern of risk groups (notably 
the absence of high-risk patients in this study) differed from 
major validation studies, such as the QUASAR (Quick And 
Simple And Reliable) trial,12 CALGB (Cancer And Leukemia 
Group B) 9581 trial,13 and NSABP (National Surgical Adju-
vant Breast and Bowel Project)-C07 study.14 The proportion 
Table 2 Patient demographics and cancer characteristics
Variables Total patients (N=95) Retrospective cohort (N=56) Prospective cohort (N=39) P-value
N (%) N (%) N (%)
age ($70 years) 54 (56.8) 31 (55.4) 23 (59.0) 0.389
sex (male) 49 (51.6) 30 (53.6) 19 (48.7) 0.681
carcinoembryonic antigen ($5 ng/ml) 24 (25.3) 14 (25.0) 10 (25.6) 1.000
Tumor location 0.407
right/transverse colon 56 (58.9) 35 (62.5) 21 (53.8)
left/sigmoid colon 39 (41.1) 21 (37.5) 18 (46.2)
harvested lymph nodes ($12) 86 (90.5) 47 (83.9) 39 (100) 0.010
histologic differentiation 0.093
Well 8 (8.4) 7 (12.5) 1 (2.6)
Moderate 86 (90.5) 49 (87.5) 37 (94.9)
Poor 1 (1.1) 0 (0) 1 (2.6)
lymphovascular invasion (+) 3 (3.2) 0 (0) 3 (7.7) 0.066
Perineural invasion (+) 2 (2.1) 0 (0) 2 (5.1) 0.087
nccn high-risk features (+)* 15 (15.8) 11 (19.6) 4 (10.3) 0.263
recurrence (+) 4 (4.2) 4 (7.1) 0 (0) 0.141
Notes: *NCCN high-risk features are defined as number of harvested lymph nodes ,12, histologically poorly differentiated, obstruction or perforation, lymphovascular 
invasion, perineural invasion, or positive margin.
Abbreviations: +, positive; nccn, national comprehensive cancer network.
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of low-risk group patients was 39.0%–43.7% in the prior 
studies12–14 yet was 64.2% in this study. Additionally, the 
proportion of Caucasian patients (White race/ethnicity) 
was predominant (88%–92%) in the previous studies.13,14 
Our results suggest that the genetic characteristics of 
CRC in Asian patients, particularly Koreans, are different 
from Western patients based on results of the quantitative 
12-multigene expression assay for colon cancer.
In previous studies, the proportion of patients older than 
70 years was 17%–35%, and the rate of less than 12 lymph 
nodes ranged from 35% to 47%;12–14 however, our study 
yielded corresponding results of 57% and 10%. Interestingly, 
high-grade tumors were much more uncommon (1%) in 
this study than in prior studies (25%–32%).12–14 Gray et al12 
observed that high-grade tumors were more frequent in the 
high-risk group than in the low-risk group (44% vs 23%). 
The authors suggested that patients with higher Recurrence 
Score® were more likely to have T4 disease, MMR-deficient 
tumors, and high-grade tumors. It is possible that, by exclud-
ing those with T4 disease and those with MMR-deficient 
tumors, our sampling process excluded patients with high-
grade tumors. The lower Recurrence Scores® in this study 
population might be attributable to the limited inclusion 
criteria. Thus, if we had included more high-grade tumors, 
the proportion of tumors in the high-risk group would likely 
have increased. However, it is possible that the absence or 
relatively low proportion of high-risk patients could be dis-
tinctive genetic characteristics of Korean patients found using 
the quantitative 12-multigene expression assay. Thus, the 
validation results of Western patients need to be cautiously 
applied to other ethnicities, including Korean patients.
In this study, only pT3N0 and MMR-proficient tumors 
were included in order to maintain a homogenous study popu-
lation. MMR gene-deficiency, also called high microsatellite 
instability, is associated with a lower recurrence risk 
in stage II colon cancer and is unlikely to benefit from 
fluorouracil-based adjuvant chemotherapy.19,21,22 Ethnic dif-
ferences of MMR-gene status have also been shown. Hong 
et al19 reported that rates of MMR gene-deficient tumors 
were ~9% in Korean CRC patients and ~18% in Western 
patients.23,24 These differences in MMR gene status suggest 
that ethnic differences are associated with gene expression. 
Our finding based on results from the quantitative 12-multi-
gene expression assay also supports the hypothesis that ethnic 
difference is associated with gene expression difference.
Three validation studies, the QUASAR trial,12 CALGB 
9581 trial,13 and NSABP-C07 study,14 showed that Recurrence 
Score® was significantly associated with recurrence risk in 
stage II12,13 or stage II and III patients.14 The prognostic 
significance of the 12-multigene expression assay has also 
been validated in rectal cancer patients. Reimers et al25 
reported that Recurrence Score® was a significant predictor 
for recurrence risk and cancer-specific survivals in stage II 
and III rectal cancer patients. In this study, we also observed 
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Figure 2 relationship between the continuous recurrence score® and 3-year 
recurrence risk.
Note: a rug plot depicting the distribution of the recurrence score® is included at 
the bottom of the figure.
Table 5 Prognostic factors for recurrence-free interval in the retrospective cohort (n=56)
Variables Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Dichotomous
sex: female vs male 0.331 (0.034–3.181) 0.338 0.514 (0.045–5.919) 0.593
Tumor location: right vs left-sided 0.775 (0.109–5.514) 0.799 1.19 (0.085–16.614) 0.897
Tumor grade: well vs moderate ,0.001 (,0.001–999.9) 0.998 ,0.001 (,0.001–999.9) 0.999
nodes examined: ,12 vs $12 1.929 (0.200–18.570) 0.570 1.98 (0.079–49.654) 0.678
nccn risk*: high vs low 1.41 (0.146–13.580) 0.767 1.223 (0.056–26.882) 0.899
continuous
age, years 0.959 (0.881–1.044) 0.335 0.96 (0.855–1.077) 0.485
recurrence score® per iQr 0.517 (0.193–1.390) 0.191 0.582 (0.203–1.672) 0.315
Notes: *NCCN high-risk features are defined as number of harvested lymph nodes ,12, histologically poorly differentiated, obstruction or perforation, lymphovascular 
invasion, perineural invasion, or positive margin.
Abbreviations: CI, confidence interval; HR, hazard ratio; IQR, interquartile range; NCCN, National Comprehensive Cancer Network; vs, versus.
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a similar pattern in that the 3-year recurrence risk increased 
with Recurrence Score®, although this association was not 
significant. Our study had only four events of recurrences; 
thus, if there were more recurrence events in our study popu-
lation, we could expect a significant relationship between 
Recurrence Score® and recurrence risk.
The main limitations of this study were the small study 
population and the fact that there were only four recurrence 
events; thus, it was difficult to obtain meaningful results 
from the multivariate risk factor analysis for recurrence-free 
survival. In addition, this study did not include patients 
with rectal cancer, which has previously been associated 
with more frequent recurrences compared with colon 
cancer.26 However, it was the first study to investigate gene 
expression patterns based on the quantitative 12-multigene 
expression assay in Korean patients with colon cancer. 
In addition, our study population was relatively homog-
enous in that it included only T3N0 tumors and MMR-
proficient tumors.
In summary, distribution patterns of risk groups based on 
Recurrence Score®, especially absence of a high-risk group, 
were different from the results of prior validation studies.12–14 
These findings suggest that ethnic differences between 
Korean and Western patients are potential contributing 
factors of differences in gene expression in the quantitative 
12-multigene expression assay. In addition, although not sig-
nificant, Recurrence Score® was associated with an increased 
3-year recurrence risk. Based on our findings, recurrence risk 
stratification based on the quantitative 12-multigene expres-
sion assay can be applied to Korean patients with stage II and 
MMR gene-proficient tumors. However, the results of the 
assay should be interpreted cautiously in Korean patients, as 
unidentified ethnic differences may exist in the gene expres-
sion pattern. Moreover, there might have been other factors 
involved in differences in gene expression in the quantitative 
12-multigene expression assay that were not addressed in 
this study. We did not evaluate another cohort of a different 
ethnicity. Accordingly, it should be determined in future 
research whether ethnicity is the main reason for the differ-
ences in Recurrence Score® in other ethnic groups. In addi-
tion, definite conclusions could not be drawn in this study due 
to the limited sample size. In future perspectives, it would be 
useful to identify single-nucleotide polymorphisms affecting 
gene expression levels of genes included in the quantitative 
12-multigene expression assay in a Korean population, and 
more genetic studies should be performed in order to validate 
exact ethnic differences in gene expression.
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